On June 25, 2023, a small capsule built by Varda Space Industries reentered Earth’s atmosphere over the Utah desert after spending 251 days in low-Earth orbit. Inside was ritonavir — a small-molecule HIV drug whose crystal structure had been grown in microgravity. The capsule’s return marked the first time a private company had manufactured a pharmaceutical product in orbit and returned it to Earth. Varda has since launched three more missions, with a fourth in orbit and a fifth planned to optimize solution-based crystallization reactors. The company has raised $329 million in total capital. Bristol Myers Squibb, Merck, and other major pharmaceutical firms have conducted ISS crystallization experiments. BioOrbit, a London startup, raised £9.8 million in 2026 to advance industrial-scale orbital protein crystallization.
Space-based pharmaceutical manufacturing has crossed from theoretical to operational. The question is no longer whether it works, but for which drugs, at what scale, and at what economic threshold it makes sense — and the answers emerging from early missions are more specific and interesting than most coverage of the field suggests.
Why Microgravity Changes Crystal Growth
The pharmaceutical relevance of microgravity rests on a specific physical mechanism. On Earth, protein solutions undergoing crystallization are subject to three forces that disrupt crystal quality: convection (fluid movement driven by temperature and concentration gradients), buoyancy (the tendency of denser regions to sink), and sedimentation (particles settling under gravity). These forces create turbulent, heterogeneous conditions around growing crystals that produce irregular sizes, internal defects, and inconsistent structures.
In microgravity, all three effects are suppressed. Convective currents essentially disappear. Buoyancy differences between crystal and solution become irrelevant. Sedimentation stops. The result, as Varda’s chief science officer Adrian Radocea explained, is that “microgravity suppresses convective currents, buoyancy, and sedimentation, and the resulting crystals are more uniform in size and structure.” The uniformity is not merely aesthetic — it has direct pharmaceutical consequences.
Crystal size and uniformity determine how a drug dissolves in the body, how it can be formulated for delivery, and in some cases whether it can be delivered subcutaneously rather than intravenously. A monoclonal antibody that forms large, uniform crystals in microgravity can potentially be reformulated as a concentrated suspension for self-injection — eliminating the hospital infusion visit that intravenous biologics currently require. BioOrbit’s platform is specifically targeting this application: producing monoclonal antibody crystals in microgravity with controlled size and uniformity to enable subcutaneous delivery of cancer treatments and other biologics that currently require hospital-based IV infusion.
The Pembrolizumab Precedent
The most documented pharmaceutical crystallization success in space involves pembrolizumab — Merck’s blockbuster cancer immunotherapy sold as Keytruda, which generated over $25 billion in revenue in 2024. A 2019 study published in npj Microgravity documented collaboration between Merck and the ISS National Lab in which microgravity crystallization of pembrolizumab produced homogeneous, high-yield crystal suspensions that improved the drug’s formulation for delivery. This work contributed directly to the development of a subcutaneous version of pembrolizumab — a formulation change that meaningfully improves patient experience and access.
The pembrolizumab case is significant not because it proves space manufacturing is the future of drug production, but because it demonstrates a concrete, documented pathway from microgravity crystallization to an improved drug formulation that reached patients. That pathway — grow better crystals in orbit, characterize their structure using high-resolution X-ray diffraction, translate the structural insights into improved terrestrial formulations — is the model that most near-term space pharma applications are pursuing.
The Commercial Ecosystem Taking Shape
Varda’s model is the most commercially advanced. The company operates unmanned autonomous manufacturing platforms that launch on commercial rockets, conduct processing in orbit over weeks to months, and return capsules to Earth via hypersonic reentry. Its focus spans small molecules and monoclonal antibodies. Four missions have been completed and returned; a fifth will focus on optimizing crystallization reactor designs. The company’s $329 million in total funding reflects investor confidence that orbital pharmaceutical manufacturing is commercially viable at some price point.
BioOrbit, founded in the UK, is targeting industrial-scale protein crystallization with a platform designed to produce hundreds of kilograms of pharmaceutical-grade crystals in orbit — a scale that would move beyond research and into actual manufacturing supply chain integration. The company launched its first orbital experiment in 2025 with The Exploration Company, testing crystal survivability through reentry conditions.
Bristol Myers Squibb has worked with ISS National Lab service provider Redwire Space on crystallization of small molecule compounds for manufacturing optimization. NASA’s NSF has funded eight consecutive years of ISS tissue engineering and mechanobiology research solicitations. The ISS National Lab has hosted dozens of pharmaceutical experiments across multiple companies and research institutions. As the ISS approaches retirement in 2030, commercial stations being developed by Axiom Space, Blue Origin and Sierra Space, VAST, and Voyager Technologies are explicitly positioning their life sciences capabilities as a continuation of the ISS pharmaceutical research legacy.
What the Economics Actually Require
The honest accounting of space pharmaceutical manufacturing requires confronting the cost structure directly. Launch costs have fallen dramatically — SpaceX Falcon 9 launches to LEO now cost roughly $2,700 per kilogram, compared to over $50,000 per kilogram in the Space Shuttle era — but returning cargo from orbit adds complexity and cost that ground-based manufacturing does not face. For most pharmaceutical products, the economics do not work. The value per kilogram must be extremely high to justify orbital manufacturing.
This is why the focus is on high-value biologics — monoclonal antibodies, enzyme replacement therapies, complex protein structures — where the value per kilogram can reach millions of dollars and where modest improvements in crystal quality or formulation can unlock substantially better drug performance or delivery options worth billions in market value. A LifeSciVC analysis published in May 2025 estimated the addressable market for space-based biomanufacturing at drugs where orbital crystallization could enable subcutaneous formulations of currently IV-only biologics — a category that includes some of the highest-revenue drugs in existence.
What Remains Speculative
The leap from improved crystal quality in orbital experiments to commercially manufactured pharmaceuticals produced in orbit rather than characterized in orbit has not been fully made. Most current missions optimize formulations that are then manufactured terrestrially — the space environment provides structural information and improved crystal seeds, not production volume. Scaling from research-scale crystallization to manufacturing hundreds of kilograms in orbit, with the quality consistency, sterility assurance, and batch-to-batch reproducibility that pharmaceutical manufacturing demands, involves engineering challenges that have not been demonstrated at commercial scale.
Regulatory frameworks for pharmaceuticals manufactured in space are undeveloped. The FDA has not yet approved a drug manufactured entirely in orbit. Establishing equivalence to terrestrial manufacturing standards, validating sterilization and containment in the space environment, and ensuring supply chain reliability when launches and reentries depend on rocket schedules introduces manufacturing risk that terrestrial facilities do not face. Long-term radiation effects on biological materials over extended orbital missions require characterization for each molecule and process.
Why It Matters
Many of the most important and expensive medicines in current development are complex biologics — large protein molecules whose therapeutic activity depends on their three-dimensional structure and the consistency of their formulation. If microgravity provides a route to better crystal structures, improved delivery formulations, and reduced manufacturing variability for these molecules, the patient benefit could be substantial: drugs that currently require hospital infusions becoming self-injectable, drugs that currently have inconsistent batch quality becoming more reliable, drugs that currently cannot be formulated at sufficient concentration becoming viable. These are not marginal improvements — they determine whether patients can access treatments in outpatient rather than hospital settings, whether drugs are affordable at volume, and whether therapeutic activity is reliable across the patient population.
Closing Human Dimension
There is something unexpected about the idea that the best place to make certain medicines is 400 kilometers above Earth, in a facility moving at 28,000 kilometers per hour, in conditions that took billions of dollars and decades of engineering to create. But the physics does not care about our intuitions about where manufacturing belongs. If the absence of gravity allows proteins to crystallize into more perfect, more uniform, more therapeutically effective structures than anything achievable on the ground — and the evidence increasingly suggests it does for specific molecules — then the most honest commitment to patient outcomes follows the physics wherever it leads, even into orbit.
Sources
1. ITIF. “Drug Development in Microgravity: The Next Frontier in Biopharmaceutical Innovation.” May 2025. https://itif.org/publications/2025/05/27/drug-development-in-microgravity-the-next-frontier-in-biopharmaceutical-innovation/
2. BioProcess International. “Varda Space Industries secures $187M for orbital pharmaceutical production.” July 2025. https://www.bioprocessintl.com/facilities-capacity/defying-gravity-while-defining-medicine-varda-secures-187m-for-space-orbital-laboratories
3. Varda Space Industries. “Differentiated drug products enabled by microgravity.” https://www.varda.com/biopharma
4. Reichert, P. et al. (2019). “Pembrolizumab microgravity crystallization experimentation.” npj Microgravity 5, 28. https://www.varda.com/science/pembrolizumab-microgravity-crystallization-experimentation/
5. AZoLifeSciences. “How BioOrbit is Building a Pharmaceutical Factory in Space.” April 2026. https://www.azolifesciences.com/article/How-BioOrbit-is-Building-a-Pharmaceutical-Factory-in-Space.aspx
6. HLTH. “BioOrbit Raises $13.2M Seed Round to Advance Space-Based Drug Manufacturing.” May 2026. https://hlth.com/insights/news/bioorbit-raises-13-2m-seed-round-to-advance-space-based-drug-manufacturing
7. LifeSciVC. “Boosters and Biologics: Is Space-Based Biomanufacturing Real?” May 2025. https://lifescivc.com/2025/05/boosters-and-biologics-is-space-based-biomanufacturing-real/
8. MobiHealthNews. “Varda Space Industries secures $187M for microgravity drug discovery.” July 2025. https://www.mobihealthnews.com/news/varda-space-industries-secures-187m-microgravity-drug-discovery
Idea generated by Grok. Article expanded with Grok, substantially rewritten with Claude Sonnet 4.6. Published at artificialideas.org.
Artificial Ideas 